- Motley Fool
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
New data indicate that its cell therapy could soon find a larger market.
- Zacks
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
- Motley Fool
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These biotech stocks have just launched their first products.
